eligibility_summary
Inclusion: Age 18–70, relapsed/refractory DLBCL or allowed subtypes, biopsy available, after 1L R‑chemo (pola allowed), CAR‑T not indicated/available, ECOG ≤2, measurable disease, adequate counts, liver, renal, HBcAb+ if HBV DNA−, not pregnant, contraception, life expectancy >6 mo. Exclusion: PMBCL/CNS lymphoma, severe mAb allergy/chemo contraindication, LVEF<50, neuropathy ≥2, active HBV/HCV RNA+/HIV/infection, recent stroke/major surgery, major organ/cardiac disease, other recent cancers, pregnancy, other trials.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05966233 (withdrawn): Phase II randomized study in relapsed/refractory DLBCL comparing R-DHAP vs POLA-R-DHAP as induction before autologous stem cell transplant. Interventions and mechanisms: Polatuzumab vedotin (antibody–drug conjugate) targets CD79b on B cells, delivers MMAE to disrupt microtubules and induce apoptosis, Rituximab (chimeric anti-CD20 monoclonal antibody) depletes B cells via CDC/ADCC and apoptosis, Dexamethasone (corticosteroid) triggers lymphocyte apoptosis via glucocorticoid receptor, Cytarabine/Ara-C (antimetabolite) inhibits DNA polymerase causing S-phase arrest, Cisplatin (platinum agent) forms DNA crosslinks causing cytotoxicity, ASCT provides hematopoietic rescue after intensive therapy. Cells/pathways targeted: malignant B cells via CD20 and CD79b (BCR component), microtubules, DNA replication/repair, and immune effector pathways.